SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization-Reference-Cited by-同舟云学术

SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization

Published:2019-02 Issue:1 Volume:30 Page:16-35
ISSN:0955-8810
Container-title:Behavioural Pharmacology
language:en
Short-container-title:

Author:

Nirogi Ramakrishna,Abraham Renny,Benade Vijay,Medapati Rajesh B.,Jayarajan Pradeep,Bhyrapuneni Gopinadh,Muddana NageswaraRao,Mekala Venkat R.,Subramanian Ramkumar,Shinde Anil,Kambhampati Ramasastry,Jasti Venkat

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Psychiatry and Mental health,Pharmacology

Reference58 articles.

1. 2016 Alzheimer’s disease facts and figures;Alzheimers Dement,2016

2. Cumulative, additive benefits of memantine–donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis;Atri;Alzheimers Res Ther,2015

3. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials;Atri;JAMA,2018

4. Memantine improves memory for taste-avoidance learning in day-old chicks exposed to isolation stress;Barber;Pharmacol Biochem Behav,2010

5. A review of central 5-HT receptors and their function;Barnes;Neuropharmacology,1999

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-08

2. First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT₆ Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease;Journal of Medicinal Chemistry;2024-01-08

3. Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents;European Journal of Medicinal Chemistry;2023-11

4. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders;Signal Transduction and Targeted Therapy;2023-05-03

5. A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease;Expert Opinion on Pharmacotherapy;2023-03-28